Andrew J. Roth

William J. Gradishar, MD, discusses the need for new strategies that could alter the landscape of HR-positive breast cancer for the better, and how these methods can overcome drug resistance and delay disease progression.

Recent, promising data for androgen receptor antagonists could propel these agents into the treatment paradigm for a large subgroup of patients with triple-negative breast cancer.

With several novel agents on the horizon, the treatment paradigm of triple-negative breast cancer is rapidly evolving and expanding its reach beyond the standard approaches.

Ghassan K. Abou-Alfa, MD, discusses research into the use of the immunotherapeutic vaccinia virus Pexa-Vec as a frontline treatment for advanced hepatocellular carcinoma.

About one quarter of patients with nonalcoholic steatohepatitis-associated hepatocellular carcinoma present without cirrhosis at diagnosis, suggesting a crucial subset of patients for future research with implications for HCC screening and surveillance.

Although regorafenib is not currently approved, Morris Sherman, MD, PhD, already views the agent as the standard second-line therapy, with hopes for moving the agent into the frontline setting.

The multikinase inhibitor midostaurin (PKC412) demonstrated an overall response rate of 60% in patients with advanced systemic mastocytosis.

A dronabinol oral solution (Syndros) has been approved by the FDA as a treatment for patients with chemotherapy-induced nausea and vomiting (CINV) in those who have not responded to conventional antiemetic therapies.

Early palliative care integrated with oncology care benefits not only patients with cancer but also family caregivers.

A multidisciplinary team led by oncology nurses can reduce both hospitalization and treatment breaks for patients with head and neck cancer.

With the growing use of oral therapies in cancer care, it is crucial that oncology nurses are using a systematic approach to assess and improve adherence, according to Whitney Perry, APRN, AOCNP.

Jeffrey Jones, MD, updated attendees at the 2016 NCCN Annual Conference on the latest developments in chronic lymphocytic leukemia.

Alan P. Venook, MD, shares insight into the evolving treatment paradigm for colorectal cancer.

After nearly 30 years of research, tumor-infiltrating lymphocyte technology is being investigated as a means of producing personalized immunotherapy for patients with metastatic melanoma in a small clinical trial that may help open the door for broader application in other solid tumor types.

Joyce O’Shaughnessy, MD, discusses how four agents—palbociclib (Ibrance), pembrolizumab (Keytruda), abemaciclib (LY2835219), and buparlisib (BKM120)—are worth examining in estrogen receptor-positive breast cancer.

With more than 8 million cancer deaths worldwide every year, the Union for International Cancer Control hopes to encourage both groups and individuals to reflect on how they can help reduce the global burden of cancer on February 4, World Cancer Day.

Combining olaratumab with doxorubicin reduced the risk of death by 54% versus doxorubicin alone in patients with advanced soft tissue sarcoma.

A novel service model that incorporated palliative care measures and shorter radiation treatment was associated with fewer unfinished treatments with radiation, shorter hospital stays, and increased use of palliative care for patients with bone metastases.

Though clinical work is ongoing and early, researchers are already considering how to manage potentially fatal neurotoxicities in patients treated with chimeric antigen receptor T-cell therapy

The addition of docetaxel to standard hormonal therapy significantly improved survival among men with newly diagnosed, hormone-naïve advanced prostate cancer.

Optimal testing strategies for breast and ovarian cancer associated with mutations in the BRCA1/2 genes, including when to start testing and which prophylactic approach to pursue, have remained a topic of debate.

Portal vein thrombosis is a dangerous and often overlooked side effect of certain gastrointestinal malignancies such as liver and pancreatic cancer, that oncology nurses need to be more proactive in managing.

The chimeric antigen receptor T-cell therapy JCAR017 elicited a 91% complete remission rate in pediatric patients with relapsed/refractory acute lymphoblastic leukemia.

Pembrolizumab elicited significantly better outcomes compared with ipilimumab in a randomized phase III trial of patients with advanced melanoma.

IMCgp100 yielded long-lasting responses in patients with advanced melanoma, according to results from a 17-patient expansion cohort presented at the 2015 AACR Annual Meeting.

To gain insight into the diagnosis and treatment of HCC, OncLive interviewed Laura Dawson, MD, FRCPC, a professor in the Department of Radiation Oncology at the University of Toronto.

A trial comparing frontline pembrolizumab with ipilimumab for the treatment of advanced melanoma has met its progression-free survival and overall survival endpoints

First-line treatment with lapatinib and a taxane failed to improve progression-free survival versus trastuzumab plus a taxane in patients with HER2-positive metastatic breast cancer in the MA.31 trial.

To gain new insight on the phase III LYM-3002 study and bortezomib's use in the frontline MCL setting, OncLive interviewed Andrew Evens, DO, MSc, director of the Tufts Cancer Center and chief of the Division of Hematology/Oncology at Tufts University School of Medicine.

The FDA has accepted a New Drug Application (NDA) for Captisol-enabled (CE) melphalan for the treatment of patients with multiple myeloma prior to autologous hematopoietic stem cell transplantation (AHCT).